These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 10910310)

  • 41. Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
    Hatlebakk JG; Berstad A
    Clin Pharmacokinet; 1996 Nov; 31(5):386-406. PubMed ID: 9118586
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Compete Research Group [corrected].
    Mason I; Millar LJ; Sheikh RR; Evans WM; Todd PL; Turbitt ML; Taylor MD
    Aliment Pharmacol Ther; 1998 Mar; 12(3):263-71. PubMed ID: 9570261
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Randomized controlled trial comparing the efficacy of mosapride plus omeprazole combination therapy to omeprazole monotherapy in gastroesophageal reflux disease.
    Yamaji Y; Isomura Y; Yoshida S; Yamada A; Hirata Y; Koike K
    J Dig Dis; 2014 Sep; 15(9):469-76. PubMed ID: 24957863
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Double-blind, placebo-controlled study of ranitidine for gastroesophageal reflux symptoms during pregnancy.
    Larson JD; Patatanian E; Miner PB; Rayburn WF; Robinson MG
    Obstet Gynecol; 1997 Jul; 90(1):83-7. PubMed ID: 9207819
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Characteristics of refractory gastroesophageal reflux disease (GERD) symptoms -is switching proton pump inhibitors based on the patient's CYP2C19 genotype an effective management strategy?
    Takeuchi T; Oota K; Harada S; Edogawa S; Kojima Y; Sanomura M; Sakaguchi M; Hayashi K; Hongoh Y; Itabashi T; Kitae H; Hoshimoto M; Takeuchi N; Higuchi K
    Intern Med; 2015; 54(2):97-105. PubMed ID: 25742999
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of gastroesophageal reflux disease: to step or not to step.
    McGuigan JE
    Am J Gastroenterol; 2001 Jun; 96(6):1679-81. PubMed ID: 11419813
    [No Abstract]   [Full Text] [Related]  

  • 47. Proton pump inhibitors or histamine-2 receptor antagonists for the prevention of recurrences of erosive reflux esophagitis: a cost-effectiveness analysis.
    Harris RA; Kuppermann M; Richter JE
    Am J Gastroenterol; 1997 Dec; 92(12):2179-87. PubMed ID: 9399748
    [TBL] [Abstract][Full Text] [Related]  

  • 48. PPIs vs H2RAs for erosive reflux esophagitis.
    King VJ
    J Fam Pract; 1998 Mar; 46(3):199-200. PubMed ID: 9519012
    [No Abstract]   [Full Text] [Related]  

  • 49. Economic analysis of alternative treatments for persistent gastro-oesophageal reflux disease.
    Hillman AL
    Scand J Gastroenterol Suppl; 1994; 201():98-102. PubMed ID: 8047833
    [TBL] [Abstract][Full Text] [Related]  

  • 50. pH, healing rate, and symptom relief in patients with GERD.
    Huang JQ; Hunt RH
    Yale J Biol Med; 1999; 72(2-3):181-94. PubMed ID: 10780580
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Omeprazole is more effective than cimetidine in the prevention of recurrence of GERD-associated heartburn and the occurrence of underlying oesophagitis.
    Bate CM; Green JR; Axon AT; Tildesley G; Murrays FE; Owen SM; Emmas C; Taylor MD
    Aliment Pharmacol Ther; 1998 Jan; 12(1):41-7. PubMed ID: 9692699
    [TBL] [Abstract][Full Text] [Related]  

  • 52. "Proton-pump inhibitor-first" strategy versus "step-up" strategy for the acute treatment of reflux esophagitis: a cost-effectiveness analysis in Japan.
    Habu Y; Maeda K; Kusuda T; Yoshino T; Shio S; Yamazaki M; Hayakumo T; Hayashi K; Watanabe Y; Kawai K
    J Gastroenterol; 2005 Nov; 40(11):1029-35. PubMed ID: 16322946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Clinical trial: the effects of adding ranitidine at night to twice daily omeprazole therapy on nocturnal acid breakthrough and acid reflux in patients with systemic sclerosis--a randomized controlled, cross-over trial.
    Janiak P; Thumshirn M; Menne D; Fox M; Halim S; Fried M; Brühlmann P; Distler O; Schwizer W
    Aliment Pharmacol Ther; 2007 Nov; 26(9):1259-65. PubMed ID: 17944740
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Helicobacter pylori-positive duodenal ulcer: three-day antibiotic eradication regimen.
    Catalano F; Branciforte G; Catanzaro R; Cipolla R; Bentivegna C; Brogna A
    Aliment Pharmacol Ther; 2000 Oct; 14(10):1329-34. PubMed ID: 11012478
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Concomitant Administration of a Histamine2 Receptor Antagonist and Proton Pump Inhibitor Enhances Gastric Acid Suppression.
    Abdul-Hussein M; Freeman J; Castell D
    Pharmacotherapy; 2015 Dec; 35(12):1124-9. PubMed ID: 26621819
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effect of wu chu yu tang on gastroesophageal reflux disease: Randomized, double-blind, placebo-controlled trial.
    Shih YS; Tsai CH; Li TC; Yu CJ; Chou JW; Feng CL; Wang KT; Lai HC; Hsieh CL
    Phytomedicine; 2019 Mar; 56():118-125. PubMed ID: 30668332
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Cost-effectiveness analysis for the treatment of non-erosive reflux disease].
    Habu Y; Fukui Y; Maruno T; Hisatsune H; Kawai K
    Nihon Rinsho; 2007 May; 65(5):951-5. PubMed ID: 17511239
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Empiric therapy for gastroesophageal reflux disease.
    Schindlbeck NE; Klauser AG; Voderholzer WA; Müller-Lissner SA
    Arch Intern Med; 1995 Sep; 155(16):1808-12. PubMed ID: 7654116
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Randomized trial of omeprazole or ranitidine versus placebo in the prevention of chemotherapy-induced gastroduodenal injury.
    Sartori S; Trevisani L; Nielsen I; Tassinari D; Panzini I; Abbasciano V
    J Clin Oncol; 2000 Feb; 18(3):463-7. PubMed ID: 10653861
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direct comparative randomised trial.
    Pouchain D; Bigard MA; Liard F; Childs M; Decaudin A; McVey D
    BMC Gastroenterol; 2012 Feb; 12():18. PubMed ID: 22361121
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.